TY - JOUR
T1 - Adult interest in using a hypothetical modified risk tobacco product
T2 - findings from wave 1 of the Population Assessment of Tobacco and Health Study (2013–14)
AU - Pearson, Jennifer L.
AU - Johnson, Amanda L.
AU - Johnson, Sarah E.
AU - Stanton, Cassandra A.
AU - Villanti, Andrea C.
AU - Niaura, Raymond S.
AU - Glasser, Allison M.
AU - Wang, Baoguang
AU - Abrams, David B.
AU - Cummings, K. Michael
AU - Hyland, Andrew
N1 - Funding Information:
Data are from wave 1 of the Population Assessment of Tobacco and Health (PATH) Study, conducted from 12 September 2013 to 15 December 2014. The PATH Study is a nationally representative, longitudinal cohort study of 45 971 adults and youth in the United States, aged 12 years and older [25]. The National Institutes of Health, through the National Institute on Drug Abuse, is partnering with the Food and Drug Administration’s Center for Tobacco Products to conduct the PATH Study under a contract with Westat. The PATH Study used Audio-Computer Assisted Self-Interviews (ACASI) available in English and Spanish to collect information on tobacco-use patterns and associated health behaviors. This analysis draws from the 32 320 adult interviews (all participants aged 18 years and older). Recruitment employed address-based, area-probability sampling, using an in-person household screener to select youths and adults. Adult tobacco users, young adults aged 18–24 and African Americans were oversampled relative to population proportions. The weighted response rate for the household screener was 54.0%. Among households that were screened, the overall weighted response rate was 74.0% for the adult interview. Further details regarding the PATH Study design and methods are published by Hyland and colleagues [26] and in the User Guide to the PATH Study restricted use files, available at http://doi.org/10.3886/ICPSR36231. Westat’s Institutional Review Board approved the study design and protocol and the Office of Management and Budget approved the data collection.
Funding Information:
K.M.C. has received grant funding from the Pfizer, Inc., to study the impact of a hospital based tobacco cessation intervention. He also receives funding as an expert witness in litigation filed against the tobacco industry.
Funding Information:
This paper is supported with Federal funds from the National Institute on Drug Abuse, National Institutes of Health, and the Food and Drug Administration, Department of Health and Human Services, under a contract to Westat (Contract no. HHSN271201100027C). The views and opinions expressed in this manuscript are those of the authors only and do not necessarily represent the views, official policy or position of the US Department of Health and Human Services or any of its affiliated institutions or agencies.
Publisher Copyright:
© 2017 Society for the Study of Addiction
PY - 2018
Y1 - 2018
N2 - Background and aims: The US Family Smoking Prevention and Tobacco Control Act provides a pathway for manufacturers to market a modified risk tobacco product (MRTP). This study examines socio-demographic and tobacco use correlates of interest in a hypothetical MRTP in a nationally representative sample of US adults. Design: Cross sectional wave 1 data from the 2013–14 Population Assessment of Tobacco and Health (PATH) Study. Setting: Household Audio-Computer Assisted Self-Interviews of US adults conducted in 2013–14. Participants: A total of 32 320 civilian, non-institutionalized adults in the United States. Measurements: Interest in using a hypothetical MRTP (‘If a tobacco product made a claim that it was less harmful to health than other tobacco products, how likely would you be to use that product?’), socio-demographics, tobacco use history and mental health and substance use problems. All estimates were weighted. Findings: Overall, 16.7% [95% confidence interval (CI) = 16.28, 17.18] of US adults reported interest in a hypothetical MRTP. Tobacco use was associated significantly with interest in a hypothetical MRTP, with interest most common among current established smokers (54.4%; 95% CI = 53.31, 55.39) and least common among never tobacco users (3.0%; 95% CI = 2.49, 3.55). Interest in a hypothetical MRTP was associated with experimental e-cigarette use among current experimental, current established and former smokers. Among non-smokers, race, age, education and substance use were associated with interest in using a hypothetical MRTP. Conclusions: Among adults in the United States, interest in using a hypothetical modified risk tobacco product is low overall, and highest among current experimental and established smokers. A small percentage of non-smokers are interested in using a hypothetical hypothetical modified risk tobacco product.
AB - Background and aims: The US Family Smoking Prevention and Tobacco Control Act provides a pathway for manufacturers to market a modified risk tobacco product (MRTP). This study examines socio-demographic and tobacco use correlates of interest in a hypothetical MRTP in a nationally representative sample of US adults. Design: Cross sectional wave 1 data from the 2013–14 Population Assessment of Tobacco and Health (PATH) Study. Setting: Household Audio-Computer Assisted Self-Interviews of US adults conducted in 2013–14. Participants: A total of 32 320 civilian, non-institutionalized adults in the United States. Measurements: Interest in using a hypothetical MRTP (‘If a tobacco product made a claim that it was less harmful to health than other tobacco products, how likely would you be to use that product?’), socio-demographics, tobacco use history and mental health and substance use problems. All estimates were weighted. Findings: Overall, 16.7% [95% confidence interval (CI) = 16.28, 17.18] of US adults reported interest in a hypothetical MRTP. Tobacco use was associated significantly with interest in a hypothetical MRTP, with interest most common among current established smokers (54.4%; 95% CI = 53.31, 55.39) and least common among never tobacco users (3.0%; 95% CI = 2.49, 3.55). Interest in a hypothetical MRTP was associated with experimental e-cigarette use among current experimental, current established and former smokers. Among non-smokers, race, age, education and substance use were associated with interest in using a hypothetical MRTP. Conclusions: Among adults in the United States, interest in using a hypothetical modified risk tobacco product is low overall, and highest among current experimental and established smokers. A small percentage of non-smokers are interested in using a hypothetical hypothetical modified risk tobacco product.
KW - Epidemiology
KW - Food and Drug Administration
KW - Population Assessment of Tobacco and Health
KW - modified risk tobacco products
KW - public health
KW - regulation
KW - study
KW - tobacco
UR - http://www.scopus.com/inward/record.url?scp=85028918365&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028918365&partnerID=8YFLogxK
U2 - 10.1111/add.13952
DO - 10.1111/add.13952
M3 - Article
C2 - 28734111
AN - SCOPUS:85028918365
VL - 113
SP - 113
EP - 124
JO - Addiction
JF - Addiction
SN - 0965-2140
IS - 1
ER -